Background Comparison of patients with coronary heart disease and controls in genome-wide association studies has revealed several single nucleotide polymorphisms (SNPs) associated with coronary heart disease. We aimed to establish the external validity of these fi ndings and to obtain more precise risk estimates using a prospective cohort design.
Introduction
Coronary heart disease is complex in origin, with contributions from lifestyle and genetic factors. 1 Family history of premature coronary heart disease is an independent risk factor, suggesting that inherited DNA sequence variants contribute to risk of the disease. Using a case-control design, genome-wide association studies have identifi ed single nucleotide polymorphisms (SNPs) at 13 genomic regions associated (p<5×10 -⁸) with coronary heart disease, myocardial infarction, or both. 2 In discovery studies, each copy of the risk allele at these loci was estimated to increase risk of myocardial infarction by 12-92%.
Discovery genome-wide association studies for myocardial infarction or coronary heart disease have ascertained cases on the basis of early age of disease onset or aff ected family members, and as such the reported eff ect estimates might not be representative of the general population. Although effi cient for discovery, crosssectional and case-control designs have the potential for several types of bias, whereas the prospective cohort study is regarded as the gold standard in epidemiological investigations. 3 Therefore, we set out to answer two questions: fi rst, are the reported genetic association fi ndings externally generalisable in studies diff ering from the discovery studies; and second, can more precise risk estimates be obtained with a prospective cohort design?
Methods

Study populations
We tested the 13 recently discovered SNPs for association with coronary heart disease in two designs: a case-control design including participants diff ering from those in the discovery samples (3829 participants with prevalent coronary heart disease and 48 897 controls free of the disease); and a prospective cohort design including 30 725 participants free of cardiovascular disease from Finland and Sweden. Coronary heart disease was defi ned as myocardial infarction, unstable angina pectoris, coronary revascularisation (coronary artery bypass graft or percutaneous transluminal coronary angioplasty), or death due to coronary heart disease. Cardiovascular disease included coronary heart disease and ischaemic stroke events. Detailed case defi nitions are described in the webappendix.
Participants from seven cohorts were included in our analyses (table 1). The FINRISK 1992, 1997, and 2002 cohorts consist of a representative random sample selected from inhabitants of diff erent regions in Finland aged 25-74 years. The survey included a mailed questionnaire and a clinical examination at which a blood sample was drawn. The study protocol has been described previously. 4 23 036 individuals participated in these cohorts and genotype data was available from 20 927 participants.
The Health 2000 study was based on a stratifi ed two-stage cluster sampling from the National Population Register to represent the total Finnish population aged 30 years and older. 5 The survey included an interview about medical history, health-related lifestyle habits, and a clinical examination at which a blood sample was drawn. 6200 people participated in the study. After exclusion of individuals older than 80 years and without suffi cient genotype data, the fi nal dataset consisted of 5796 participants. A detailed methodology report is available online. 6 The Malmö Diet and Cancer (MDC) study was a community-based prospective epidemiological cohort of 28 449 people recruited for a baseline examination between 1991 and 1996. 7 From this cohort, 6103 people were randomly selected to participate in the Cardiovascular Cohort (MDC-CC), which sought to investigate risk factors for cardiovascular disease. All participants underwent a medical history, physical examination, and laboratory assessment for cardiovascular risk factors, as described previously. 8 Final data with genotypes were available for 5104 participants.
During follow-up of the FINRISK and HEALTH 2000 cohorts, data for admission to hospital and mortality were obtained from the Finnish National Hospital Discharge Register and the Finnish National Causes-of-Death Register. These registers have excellent validity and coverage. 9, 10 Follow-up ended on Dec 31, 2007. Follow-up of the MDC-CC is as previously described. 11 The Malmö Preventive Project (MPP) is a cohort from southern Sweden that was set up in 1974. 33 346 individuals were screened during 1974-92. Information concerning lifestyle factors and medical history was obtained from a questionnaire. All participants underwent physical examination and biochemical analyses. Of individuals 12 For each case, two controls matched by sex and birth year and free of acute coronary syndrome were sampled. In total, 2101 cases and 3914 controls (of which 1453 were unique) formed the fi nal genotyped COROGENE casecontrol sample.
The FINRISK 1992 FINRISK , 1997 FINRISK , 2002 and Health 2000 study protocols were approved by the ethics committee of the National Institute for Health and Welfare, the MDC-CC and MPP study protocols by the ethics committee of Lund University, and the COROGENE study protocol by the ethics committee of Helsinki University Hospital, Internal Medicine. All participants provided written informed consent.
SNP selection and genotyping
We selected SNPs from genome-wide association studies published before June, 2009 in which phenotypes studied were myocardial infarction or coronary heart disease, and association between a SNP and myocardial infarction or coronary heart disease exceeded a genome-wide association threshold (p<5×10 -⁸). 13 SNPs from seven reports [13] [14] [15] [16] [17] [18] [19] met these criteria, including 1q41 in MIA3, 1p32 near 
Statistical analysis
We tested associations between SNPs and incident cardiovascular events using Cox proportional hazards 20 We constructed a multilocus genetic risk score for each individual by summing the number of risk alleles (0/1/2) for each of the 13 SNPs weighted by their estimated eff ect sizes in the discovery sample (table 2 shows SNP specifi c weights). Missing genotype values were imputed with the cohort-specifi c averages of risk allele frequencies.
Estimates of association between the genetic risk score divided into quintiles and time to coronary heart disease, cardiovascular disease, and myocardial infarction were calculated with Cox proportional hazards models. For each cohort we calculated 95% CIs for hazard ratios (HRs) and tested the null hypothesis of no linear eff ect over the quintiles using 1 df Wald test.
For prevalent case-control analyses, we analysed individual SNP and quintiles of genetic risk score associations using a logistic regression model adjusted for age and sex. COROGENE data were analysed with conditional logistic regression. Each cohort was analysed separately, and the estimates weighted on the inverse of their standard errors were combined across cohorts with fi xed eff ects meta-analysis. 21 To evaluate the potential value of genetic risk score in risk prediction, we used two cohorts (FINRISK 1992 and 1997 ) and up to 10-year follow-up. First, we compared the receiver operating characteristic (ROC) curves 22 of models with and without genetic risk score. The statistical signifi cance of change in the area under the ROC curve (AUC) between models was tested with the correlated C-index approach. 23 Second, we calculated net reclass ifi cation improvement (NRI) and clinical NRI 24 using the Kaplan-Meier approach with bootstrap-based p values, 25 and integrated discrimination improve ment (IDI). 26 The model calibration was tested with Hosmer-Lemeshow goodness-of-fi t test.
Since each of the 13 reported SNPs has previously been associated with coronary heart disease or myocardial infarction at signifi cance levels exceeding a stringent genome-wide threshold, in this report we regarded an association to be signifi cant if a twosided p value was less than 0·05 (for the same risk allele in the same direction as in the original report). The R statistical package (version 2.11.1) was used for all analyses.
Role of the funding source
The sponsors had no role in the conduct or interpretation of the study. The corresponding author had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. HR (95% CI) for CHD (total n=25 243)
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HR=hazard ratio. Table 1 shows background characteristics along with risk factor distributions for the cohorts.
In single SNP analyses for prevalent cases, 9p21 near CDKN2A-CDKN2B, 21q22 near SLC5A3-MRPS6-KCNE2, and 1q41 in MIA3 were associated with coronary heart disease, cardiovascular disease, and myocardial infarction, and 19p13 near LDLR was associated with prevalent coronary heart disease (webappendix p 2). In analysis of incident cases, 6q26 in LPA and 9p21 near CDKN2A-CDKN2B were associated with all three endpoints. Additionally, 6p24 in PHACTR1 was associated with incident coronary heart disease and cardiovascular disease, 12q24 in SH2B3 with cardiovascular disease and myocardial infarction, and 21q22 near SLC5A3-MRPS6-KCNE2 with coronary heart disease and myocardial infarction (table 2) . Overall, seven of the 13 variants were associated in at least one analysis.
Genetic risk score was strongly associated with incident coronary heart disease, cardiovascular disease, and myocardial infarction when adjusted for age and sex (webappendix p 3) and traditional risk factors (table 3) . Adjustment for traditional risk factors did not substantially change the estimates from the model adjusted for age and sex only. Participants in the top quintile of genetic risk score were estimated to have 1·66-times increased risk of coronary heart disease compared with those in the bottom quintile (95% CI 1·35-2·04, p value for linear trend across the quintiles=7·3×10 -¹⁰), 1·50-times increased risk of cardiovascular disease (95% CI 1·29-1·75, p=1·9×10 -¹⁰), and 1·46-times increased risk of myocardial infarction (95% CI 1·15-1·86, p=2·8×10 -⁵).
Results were broadly similar when the genetic risk score was divided into tertiles. In models adjusted for traditional risk factors, participants in the top tertile of the genetic risk score were estimated to have a 1·56-times increased risk of coronary heart disease compared with those in the bottom tertile (95% CI 1·33-1·83, p value for linear trend across tertiles=2·8×10 -⁸), 1·40-times increased risk of cardiovascular disease (95% CI 1·24-1·58, p=1·4×10 -⁸), and 1·34-times increased risk of myocardial infarction (95% CI 1·12 -1·62, p=0·0015).
The genetic risk score conferred risk comparable to other established risk factors such as plasma LDL cholesterol (HR 2·08, 95% CI 1·57-2·76, for top vs bottom quintile of LDL cholesterol in FINRISK studies), systolic blood pressure (HR 1·66, 95% CI 1·19-2·30, for top vs bottom quintile of systolic blood pressure in FINRISK studies), or plasma C-reactive protein (HR 1·79, 95% CI 1·15-2·80, for top vs bottom quintile in FINRISK studies). Although the group means were statistically diff erent, the distribution of each quantitative risk factor between those who went on to develop coronary heart disease and those who did not was broadly overlapping (fi gure). Table 4 shows results for prevalent events. The odds ratio for coronary heart disease between the highest and lowest quintile group was 1·63 (95% CI 1·24-2·15, p=4·8×10 -⁵), for cardiovascular disease was 1·30 (95% CI 1·15-1·47, p=2·6×10 -⁸), and for myocardial infarction was 1·56 (95% CI 1·38-1·76, p=1·2×10 -¹⁵).
Additionally, we investigated whether adjustment for a history of early-onset myocardial infarction among fi rst-degree relatives changed genetic risk score estimates in the FINRISK studies. Family history was signifi cantly associated with incident events (HR for coronary heart disease 1·40, 95% CI 1·20-1·64; webappendix p 4), but the eff ect of the genetic risk score did not change after adjustment for family history (webappendix p 5).
We then investigated whether the genetic risk score association was dominated by rs4977574 at 9p21 near CDKN2B-CDKN2A, which is the strongest myocardial infarction locus reported to date. After adjustment for rs4977574, the HR between the highest and lowest genetic risk score quintile was 1·51 (95% CI 1·19-1·91) for coronary heart disease. Thus, other variants in the genetic risk score seem to have predictive power beyond the 9p21 locus (webappendix p 5). The AUC estimates for coronary heart disease, cardiovascular disease, and myocardial infarction models with traditional risk factors and genetic risk score were 0·872, 0·853, and 0·881, respectively, and they were not signifi cantly higher than the estimates from the models with only traditional risk factors (0·871, p=0·19; 0·853, p=0·48; and 0·880, p=0·35, for coronary heart disease, cardiovascular disease, and myocardial infarction, respectively). Table 5 and table 6 show risk reclassifi cation results for coronary heart disease. When participants were classifi ed into four risk categories (0-5%, 5-10%, 10-20%, and >20%) on the basis of their 10-year predicted risk, 22 (13%) participants with coronary heart disease classifi ed at 10-20% risk category in the model with traditional risk factors changed their risk category into the greater than 20% category when genetic risk score was included in the model. Similarly, 54 (13%) of the participants without incident coronary heart disease were reclassifi ed from the greater than 20% to the 10-20% category. IDI was signifi cant for coronary heart disease (IDI 0·004, p=0·0006), cardiovascular disease (IDI 0·004, p=0·0004), and for myocardial infarction (IDI 0·003, p=0·03). For coronary heart disease, overall NRI was not signifi cant (NRI 2·2%, p=0·182), but there was a signifi cant improvement in reclassifi cation of participants at intermediate risk (clinical NRI 9·7%, p=3×10 -⁶). The calibration of the models with (p=0·52) and without (p=0·47) genetic risk score was good.
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Discussion
Using case-control and prospective cohort samples independent from the discovery samples, we sought to validate recently discovered genetic risk factors for coronary heart disease and to estimate the magnitude of risk conferred by these genetic risk factors in the population setting. We found that a genetic risk score including 13 SNPs associated with coronary heart disease or myocardial infarction was associated with risk of prevalent and incident coronary heart disease (even after we accounted for traditional risk factors), and that the 20% of individuals of European ancestry who carry the most risk alleles have a roughly 1·7-times increased risk of coronary heart disease when compared with those in the lowest quintile. These fi ndings allow us to draw several conclusions. First, the results from case-control discovery samples do seem to generalise to independent samples, including those from prospective cohorts. Second, the magnitude of eff ect conferred by genetic risk score (roughly 1·7-times increased risk in our study) is attenuated when compared with the discovery reports (about 2·2-times in one report 9 ). Third, even though family history of early-onset cardiovascular disease raised the risk of cardiovascular events by 25-40%, adjustment for family history had no eff ect on the risk estimates because of the genetic risk score. In view of measurement error for family history, and since genetic variants only account for a small proportion of familial risk, this fi nding might not be unexpected.
Finally, although strongly associated with risk of incident coronary heart disease, genetic risk score did not improve risk discrimination when assessed by the C index. This fi nding of a biomarker being associated with incident disease but yet not improving risk discrimination has been seen with several other biomarkers, including C-reactive protein and B-type natriuretic peptide, among others. 27 Since some have argued that the C index might be an insensitive measure of risk discrimination, newer approaches have been developed, including IDI, NRI, and clinical NRI. The tested genetic risk score slightly improved risk prediction for coronary heart disease and myocardial infarction when assessed by IDI and clinical NRI. Overall, these results emphasise the challenge of risk prediction for complex traits on the basis of any single factor. 28 Our combined results show much larger risk diff erences between the tails of genetic risk score than in a recently reported follow-up study of women enrolled in a clinical trial. 29 The diff erence cannot be accounted for by the inclusion of men in our study, since our estimates and predictions are similar for both sexes. Also, nine of the genetic loci in our genetic risk score are the same as in the cardiovascular disease score reported by Paynter and colleagues, 29 and the statistical models are comparable. We suggest three potential reasons for the diff ering results. Paynter and co-workers included a range of endpoints such as strokes (203 of the 777 outcomes) that have not been associated with the genetic variants studied. The inclusion of such outcomes might have diminished their eff ect estimates. Second, Paynter and colleagues had a small number of myocardial infarction events (199 events) and thus lower statistical power might account for the absence of association in that study. Finally, the women studied were a selected set of health professional participants who volunteered for the clinical trial and as such might not represent the full range of risk seen in the general population.
Although we present the largest eff ort to date to study the association between genetic risk score and risk of incident cardiovascular disease, our results should be interpreted in the context of several potential limitations. Our SNP panel could be incomplete. For example, we did not systematically evaluate SNPs related to cardiovascular risk markers, as Paynter and colleagues did. 29 Whereas hundreds of blood biomarkers have been shown to be associated with cardiovascular disease in observational epidemiology research, few have been proven to causally relate to the disease; plasma LDL cholesterol and lipoprotein(a) are notable exceptions. Therefore, we did not consider SNPs that are only associated with cardiovascular risk markers. Our study was undertaken in individuals of Swedish and Finnish descent and hence the results might not be generalisable to others in Europe or to other ancestries. We divided the continuous genetic risk score into fi ve groups and compared risk between the top and bottom quintiles. Since alternative categorisations are possible we also generated comparisons of the top and bottom third of the distribution, and these results were similar to those seen with quintiles. NRI=net reclassifi cation improvement. *Comparison of models with and without genetic risk score, adjusted for sex, LDL and HDL cholesterol, smoking, body-mass index, systolic and diastolic blood pressure, blood pressure treatment, and diabetes; age was used as the timescale. †NRI for the subset of participants in 5-20% risk category in the model without genetic risk score, with risk classes 0-5%, 5-20%, and >20%. 23 Table 6 : Net reclassifi cation improvement of genetic risk score for coronary heart disease in the FINRISK 1992 and 1997 cohorts*
In conclusion, a genetic risk score based on 13 SNPs from genome-wide association studies for myocardial infarction and coronary heart disease was associated with a fi rst coronary heart disease event, with a relative risk estimate of 1·7 between the highest and lowest quintiles of genetic risk score. Genetic risk score improved risk reclassifi cation in participants who were at intermediate risk on the basis of traditional risk factors. Whether this genetic risk score will have clinical usefulness remains to be defi ned in future studies.
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